Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Echuan Tan, Tao Wan, Qi Pan, Jianan Duan, Song Zhang, Ruijue Wang, Peng Gao, Jia Lv, Hui Wang, Dali Li, Yuan Ping, Yiyun Cheng
Developing protein drugs that can target intracellular sites remains a challenge due to their inadequate membrane permeability. Efficient carriers for cytosolic protein delivery are required for protein-based drugs, cancer vaccines, and CRISPR-Cas9 gene therapies. Here, we report a screening process to identify highly efficient materials for cytosolic protein delivery from a library of dual-functionalized polymers bearing both boronate and lipoic acid moieties. Both ligands were found to be crucial for protein binding, endosomal escape, and intracellular protein release...
April 19, 2024: Science Advances
#22
JOURNAL ARTICLE
Xiufang Liu, Ning Rong, Zhenhua Tian, Joseph Rich, Lili Niu, Pengqi Li, Laixin Huang, Yankai Dong, Wei Zhou, Pengfei Zhang, Yizhao Chen, Congzhi Wang, Long Meng, Tony Jun Huang, Hairong Zheng
Transfected stem cells and T cells are promising in personalized cell therapy and immunotherapy against various diseases. However, existing transfection techniques face a fundamental trade-off between transfection efficiency and cell viability; achieving both simultaneously remains a substantial challenge. This study presents an acoustothermal transfection method that leverages acoustic and thermal effects on cells to enhance the permeability of both the cell membrane and nuclear envelope to achieve safe, efficient, and high-throughput transfection of primary T cells and stem cells...
April 19, 2024: Science Advances
#23
JOURNAL ARTICLE
Robert C Walker, Jack Harrington, Stella P Breininger, Oliver Pickering, Samuel L Hill, Benjamin P Sharpe, Ben Grace, Ian Reddin, Rushda Rajak, Antigoni Manousopoulou, Spiros D Garbis, Zoë S Walters, Matthew J J Rose-Zerilli, Timothy J Underwood
No abstract text is available yet for this article.
April 3, 2024: British Journal of Surgery
#24
JOURNAL ARTICLE
Jon Zugazagoitia, Handerson Osma, Javier Baena, Álvaro C Ucero, Luis Paz-Ares
Platinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and consistent increase of long-term survival with PD-1 axis inhibition, the magnitude of the benefit from immunotherapy appears lower as compared to other solid tumors. Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including, among others, T cell exclusion, downregulation of components of the MHC-class I antigen processing and presentation machinery, or upregulation of macrophage inhibitory checkpoints...
April 17, 2024: Clinical Cancer Research
#25
JOURNAL ARTICLE
Kwazi Gabuza, Thendo I Mabuda, Oelfah Patel, Noxolo Khuboni, Ruzayda van Aarde, Sylvia Riedel, Nonhlakanipho F Sangweni, Shantal Windvogel, Rabia Johnson, Christo J F Muller
BACKGROUND: Currently, it is acknowledged that vitamin E, insulin sensitizers and anti-diabetic drugs are used to manage non-alcoholic fatty liver disease (NAFLD), however, these therapeutic interventions harbour adverse side effects. Pioglitazone, an anti-diabetic drug, is currently the most effective therapy to manage NAFLD. The use of natural medicines is widely embraced due to the lack of evidence of their negative side effects. Rooibos has been previously shown to decrease inflammation and oxidative stress in experimental models of diabetes, however, this is yet to be explored in a setting of NAFLD...
2024: PloS One
#26
JOURNAL ARTICLE
Melina Peressini, Rosario Garcia-Campelo, Bartomeu Massuti, Cristina Marti, Manuel Cobo, Vanesa Gutiérrez, Manuel Dómine, Jose Fuentes, Margarita Majem, Javier de Castro, Juan Felipe Cordoba, Maria Pilar Diz, Dolores Isla, Emilio Esteban, Enric Carcereny, Laia Vila, Alberto Moreno-Vega, Silverio Ros, Amaia Moreno, Francisco Javier Garcia, Gerardo Huidobro, Carlos Aguado, Victor Cebey-Lopez, Javier Valdivia, Ramon Palmero, Pilar Lianes, Marta Lopez-Brea, Oscar Juan Vidal, Mariano Provencio, Edurne Arriola, Javier Baena, Mercedes Herrera, Helena Bote, Magdalena Molero, Vera Adradas, Santiago Ponce-Aix, Angel Nuñez-Buiza, Álvaro Ucero, Susana Hernandez, Fernando Lopez-Rios, Esther Conde, Luis Paz-Ares, Jon Zugazagoitia
BACKGROUND: Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small-cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and to identify biomarkers of long-term chemoimmunotherapy benefit in human ES-SCLC. PATIENTS AND METHODS: We analyzed tumor samples from 58 ES-SCLC patients enrolled in two multicenter single-arm phase IIIb studies evaluating front-line chemoimmunotherapy in Spain: n=32 from the IMfirst trial, and n=26 from the CANTABRICO trial...
April 17, 2024: Clinical Cancer Research
#27
JOURNAL ARTICLE
Yuhan Wen, Xiwei Shen, Yan Shen
In recent years, virtual reality (VR) technology has emerged as a powerful tool in the field of therapeutic landscapes. For hospitalized patients or individuals with limited mobility, VR provides highly personalized therapy by simulating authentic natural environments within a safe, convenient, and engaging setting. This study investigated the effectiveness of immersing patients in virtual natural environments for health recovery and compared the varying impacts of different types of landscapes on patients' recovery levels...
2024: PloS One
#28
REVIEW
Fan Guo, Yan Li, Wenjun Yu, Yuanlei Fu, Jing Zhang, Haiqiang Cao
Small interfering RNAs (siRNAs) are promising therapeutic strategies, and five siRNA drugs have been approved by the Food and Drug Administration (FDA) and the European Commission (EC). This marks a significant milestone in the development of siRNA for clinical applications. The approved siRNA agents can effectively deliver siRNAs to the liver and treat liver-related diseases. Currently, researchers have developed diverse delivery platforms for transporting siRNAs to different tissues such as the brain, lung, muscle, and others, and a large number of siRNA drugs are undergoing clinical trials...
April 17, 2024: Molecular Pharmaceutics
#29
JOURNAL ARTICLE
Eugene Brusilovskiy, Mark S Salzer, Amber Pomponio Davidson, Cecilia Feeley, Beth Pfeiffer
IMPORTANCE: Community participation of autistic adults is important for health and well-being. Many clinical efforts and interventions aim to enhance community participation in this population. OBJECTIVE: To empirically examine the relationship between community participation and community mobility. DESIGN: A randomized controlled trial using data from baseline and 4- to 6-wk follow-up. SETTING: Community organizations serving autistic adults in Philadelphia...
May 1, 2024: American Journal of Occupational Therapy: Official Publication of the American Occupational Therapy Association
#30
JOURNAL ARTICLE
Sharon Pfleger
No abstract text is available yet for this article.
April 17, 2024: International Journal of Pharmacy Practice
#31
JOURNAL ARTICLE
Kate Wortley, Stefano Carda, Carl Ganzert, Jordan Farag, Rajiv Reebye
Casting is an effective adjunctive treatment which increases the effects of botulinum toxin on patients with spasticity. The evidence for casting as an adjunctive therapy post-botulinum toxin has been well documented in the literature. However, standardized casting protocols are lacking, with no published descriptions of upper limb casting application post-botulinum toxin injection for spasticity. In this paper we will describe our experience regarding the application of upper limb casting as an adjunctive therapy for elbow spasticity, detailing indications, contraindications and description of our protocol (materials required and technique)...
April 9, 2024: American Journal of Physical Medicine & Rehabilitation
#32
JOURNAL ARTICLE
Ramin B Arani, Jessie Wang, Dong Pang, Samriddhi Buxy Sinha, Martina Uttenreuther-Fischer, Shein-Chung Chow
Biosimilar development refers to the process of creating a biologic drug that is similar to an existing approved biologic drug, also known as a reference drug. Due to the complex nature of biologics drugs and the inherent variability in their manufacturing process biosimilars are not identical but highly similar to the reference drug in terms of quality, safety, and efficacy. Efficacy and safety trials for biosimilars involve large numbers of patients to confirm comparable clinical performance of the biosimilar and the reference product in appropriately sensitive clinical indications and for appropriate sensitive endpoints...
April 17, 2024: Journal of Biopharmaceutical Statistics
#33
REVIEW
Navigating resistance to ALK inhibitors in the Lorlatinib Era: a comprehensive perspective on NSCLC.
Maria Gemelli, Adriana Albini, Gianpiero Catalano, Matteo Incarbone, Maria Cannone, Emanuela Balladore, Riccardo Ricotta, Giuseppe Pelosi
INTRODUCTION: The emergence of anaplastic lymphoma kinase (ALK) rearrangements in non-small cell lung cancer (NSCLC) has revolutionized targeted therapy. This dynamic landscape, featuring novel ALK inhibitors and combination therapies, necessitates a profound understanding of resistance mechanisms for effective treatment strategies. Recognizing two primary categories - on-target and off-target resistance - underscores the need for comprehensive assessment. AREAS COVERED: This review delves into the intricacies of resistance to ALK inhibitors, exploring complexities in identification and management...
April 17, 2024: Expert Review of Anticancer Therapy
#34
JOURNAL ARTICLE
New Treatment modality for Burn Injury Related ARDS : High-Flow Nasal Oxygen Therapy in Major Burns.
Merve Akin, Huriye Bilge Tuncer, Ali Emre Akgün, Ezgi Erkılıç
Pulmonary insufficiency is the primary cause of death in cases of major burns accompanied by inhalation damage. It is important to consider the impact on the face and neck in flame burns. Early implementation of bronchial hygiene measures and oxygenation treatment in inhalation injury can reduce mortality. This case series presents the effects of high-flow nasal oxygen application on patient outcomes in major burns and inhalation injury. This report discusses three different patients. One patient, a 29-year-old male with 35% TBSA burns, received high-flow nasal oxygen (HFNO) treatment for inhalation injury on the sixth day after the trauma...
April 17, 2024: Journal of Burn Care & Research: Official Publication of the American Burn Association
#35
JOURNAL ARTICLE
Harrison J Hansford, Matthew D Jones, Aidan G Cashin, Raymond Wjg Ostelo, Alessandro Chiarotto, Sam A Williams, Saurab Sharma, John M Rose, Jack J Devonshire, Michael C Ferraro, Michael A Wewege, James H McAuley
OBJECTIVE: To identify the smallest worthwhile effect (SWE) of exercise therapy for people with non-specific chronic low back pain (CLBP). DESIGN: Discrete choice experiment. METHODS: The SWE was estimated as the lowest reduction in pain that participants would consider exercising worthwhile, compared to not exercising i.e., effects due to natural history and other components (e.g., regression to the mean). We recruited English-speaking adults in Australia with non-specific CLBP to our online survey via email obtained from a registry of previous participants and advertisements on social media...
April 17, 2024: Journal of Orthopaedic and Sports Physical Therapy
#36
JOURNAL ARTICLE
Eddy Saad, Georges Gebrael, Karl Semaan, Marc Eid, Renée Maria Saliby, Chris Labaki, Nicolas Sayegh, J Connor Wells, Kosuke Takemura, Matthew Scott Ernst, Audreylie Lemelin, Naveen S Basappa, Lori A Wood, Thomas Powles, D Scott Ernst, Aly-Khan A Lalani, Neeraj Agarwal, Wanling Xie, Daniel Y C Heng, Toni K Choueiri
BACKGROUND: Current tobacco smoking is independently associated with decreased overall survival (OS) among patients with metastatic renal cell carcinoma (mRCC) treated with targeted monotherapy (VEGF-TKI). Herein, we assess the influence of smoking status on the outcomes of patients with mRCC treated with the current first-line standard of care of immune checkpoint inhibitor (ICI)-based regimens. MATERIALS AND METHODS: Real-world data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) were collected retrospectively...
April 17, 2024: Oncologist
#37
JOURNAL ARTICLE
Priscila Radu, Gayathri Kumar, Amanda Cole, Aikaterini Fameli, Mark Guthrie, Lieven Annemans, Jan Geissler, Antoine Italiano, Brian O'Rourke, Entela Xoxi, Lotte Steuten
BACKGROUND: Genomic and molecular alterations are increasingly important in cancer diagnosis, and scientific advances are opening new treatment avenues. Precision oncology (PO) uses a patient's genomic profile to determine optimal treatment, promising fewer side effects and higher success rates. Within PO, tumor-agnostic (TA) therapies target genomic alterations irrespective of tumor location. However, traditional value frameworks and approval pathways pose challenges which may limit patient access to PO therapies...
April 17, 2024: Oncologist
#38
JOURNAL ARTICLE
Akash Goel, Bhavya Kapoor, Hillary Chan, Karim Ladha, Joel Katz, Hance Clarke, Janneth Pazmino-Canizares, Zaaria Thomas, Kaylyssa Philip, Gabriella Mattina, Paul Ritvo
BACKGROUND: Chronic pain affects approximately 8 million Canadians (~20%), impacting their physical and mental health while burdening the health care system with costs of upwards of US $60 billion a year. Indeed, patients are often trialed on numerous medications over several years without reductions to their symptoms. Therefore, there is an urgent need to identify new therapies for chronic pain to improve patients' quality of life, increase the availability of treatment options, and reduce the burden on the health care system...
April 17, 2024: JMIR Research Protocols
#39
JOURNAL ARTICLE
Ravi B Patel, Frank E Silvestry, Jan Komtebedde, Scott D Solomon, Gerd Hasenfuß, Sheldon E Litwin, Barry A Borlaug, Matthew J Price, Rami Kawash, Scott L Hummel, Donald E Cutlip, Martin B Leon, Dirk J van Veldhuisen, Andreas J Rieth, Scott McKenzie, Heiko Bugger, Jeremy A Mazurek, Samir R Kapadia, Marc Vanderheyden, Bonnie Ky, Sanjiv J Shah
IMPORTANCE: Although the results of A Study to Evaluate the Corvia Medical Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients with Heart Failure (REDUCE LAP-HF II) trial were neutral overall, atrial shunt therapy demonstrated potential efficacy in responders (no latent pulmonary vascular disease and no cardiac rhythm management device). Post hoc analyses were conducted to evaluate the effect of shunt vs sham stratified by responder status. OBJECTIVE: To evaluate the effect of atrial shunt vs sham control on cardiac structure/function in the overall study and stratified by responder status...
April 17, 2024: JAMA Cardiology
#40
JOURNAL ARTICLE
Yi Li, Jing Li, Bin Wang, Quanmin Jing, Yujie Zeng, Aijie Hou, Zhifang Wang, Aijun Liu, Jinliang Zhang, Yaojun Zhang, Ping Zhang, Daming Jiang, Bin Liu, Jiamao Fan, Jun Zhang, Li Li, Guohai Su, Ming Yang, Weihong Jiang, Peng Qu, Hesong Zeng, Lu Li, Miaohan Qiu, Leisheng Ru, Shaoliang Chen, Yujie Zhou, Shubin Qiao, Gregg W Stone, Dominick J Angiolillo, Yaling Han
IMPORTANCE: Purinergic receptor P2Y12 (P2Y12) inhibitor monotherapy after a certain period of dual antiplatelet therapy (DAPT) may be an attractive option of maintenance antiplatelet treatment for patients undergoing percutaneous coronary intervention (PCI) who are at both high bleeding and ischemic risk (birisk). OBJECTIVE: To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing DAPT with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in birisk patients with acute coronary syndromes (ACS)...
April 17, 2024: JAMA Cardiology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
